BioCardia Announces US Patent on Imaging System for Targeting Cardiac Therapies
Excerpt from the Press Release:
SUNNYVALE, Calif., June 15, 2022 (GLOBE NEWSWIRE) — BioCardia®, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announces that the United States Patent Office has granted Patent Number 11,357,463: titled, “Target Site Selection, Entry and Update With Automatic Remote Image Annotation”, with a patent term that will expire in late 2034.
The patent describes advances for image guided delivery of treatments for the heart, describing procedures using interventional biotherapeutic delivery technologies to deliver biologics to specific target sites in the heart. The patented imaging system is designed to enable physicians to bring a previously obtained three-dimensional image of a patient’s heart from either MRI or CT scan into a procedure, predefine target sites and annotate the heart images to prepare for therapeutic intervention, and then deliver therapy to these target sites in a controlled fashion.
“A BioCardia fusion imaging system for cardiac biotherapeutics builds on the work of other respected scientists and is expected to be regulated by a 510(k) pathway, be inexpensive to develop, and work well with all of our approved and development stage delivery catheter systems, including those designed to use electrical signals to position and target therapies in the heart,” said Dr. Peter Altman, BioCardia’s President and CEO.
Click the button below to read the entire Press Release:
Discover What Sets TrialStat Apart From Ordinary EDC Platforms
Click the image or button below to explore our eClinical Suite Platform and discover what sets TrialStat apart from competing EDC platforms.
Request Your Demo Today!
From rapid database build through database lock, we deliver consistent quality on-time and on-budget. Ready to upgrade your eClinical toolkit?